(Q38025444)

27 August 2017

Intraocular corticosteroids for posterior segment disease: 2012 update (English)

1 reference

27 August 2017

Daniel F Kiernan

1

1 reference

PubMed ID

22783878

27 August 2017

William F Mieler

series ordinal

2

1 reference

PubMed ID

22783878

27 August 2017

language of work or name

English

0 references

publication date

12 July 2012

1 reference

Expert Opinion on Pharmacotherapy

27 August 2017

1 reference

27 August 2017

13

1 reference

27 August 2017

12

1 reference

27 August 2017

1679-1694

1 reference

Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration

27 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Triamcinolone acetonide in ocular therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Intravitreal triamcinolone in the treatment of serous retinal detachment in Vogt-Koyanagi-Harada syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Particle size and drug interactions of injectable corticosteroids used in ophthalmic practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

A randomized, placebo-controlled clinical trial of intravitreal triamcinolone for refractory diabetic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Intravitreal triamcinolone for refractory pseudophakic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Intravitreal triamcinolone acetonide for pseudophakic cystoid macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Intravitreal triamcinolone acetonide for the treatment of chronic pseudophakic cystoid macular oedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Prevalent misconceptions about acute retinal vascular occlusive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Effect of triamcinolone acetonide on vascular endothelial growth factor and occludin levels in branch retinal vein occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Probenecid inhibition of the outward transport of fluorescein across the human blood-retina barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Intravitreal triamcinolone acetonide for patients with macular oedema due to central retinal vein occlusion in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Intravitreal triamcinolone acetonide in patients with macular oedema due to central retinal vein occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Efficacy of intravitreal triamcinolone for the treatment of macular edema secondary to branch retinal vein occlusion in eyes with or without grid laser photocoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Intravitreal triamcinolone acetonide for treatment of persistent macular oedema in branch retinal vein occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Intravitreal triamcinolone acetonide: a change in a paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implications for macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Neovascular glaucoma treated by intravitreal triamcinolone acetonide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Effects of triamcinolone acetonide on microglial morphology and quantitative expression of MHC-II in exudative age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

ICGA-guided laser photocoagulation of occult choroidal neovascularization in age-related macular degeneration. Indocyanine green angiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Intereye difference in exudative age-related macular degeneration with minimally classic or occult subfoveal neovascularization after unilateral intravitreal injection of triamcinolone acetonide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Choroidal neovascular membranes treated with photodynamic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Triamcinolone acetonide as adjunctive treatment to verteporfin in neovascular age-related macular degeneration: a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Vital dyes for chromovitrectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Triamcinolone-assisted pars plana vitrectomy for proliferative vitreoretinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Staining of the internal limiting membrane with intravitreal triamcinolone acetonide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Triamcinolone-assisted internal limiting membrane peeling during idiopathic macular hole surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Triamcinolone acetonide preparations: impact of crystal size on in vitro behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Clinical evaluation of the safety and efficacy of preservative-free triamcinolone (triesence [triamcinolone acetonide injectable suspension] 40 mg/ml) for visualization during pars plana vitrectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Intraocular implants for extended drug delivery: therapeutic applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Visual and anatomic outcomes associated with posterior segment complications after ganciclovir implant procedures in patients with AIDS and cytomegalovirus retinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Efficacy of low-release-rate fluocinolone acetonide intravitreal implants to treat experimental uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Outcome of fluocinolone acetonide implant (Retisert) reimplantation for chronic noninfectious posterior uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Cytomegalovirus retinitis after fluocinolone acetonide (Retisert) implant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Fluocinolone acetonide sustained drug delivery device for chronic central retinal vein occlusion: 12-month results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Development, implantation, in vivo elution, and retrieval of a biocompatible, sustained release subretinal drug delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Increased incidence of sterile endophthalmitis after intravitreal triamcinolone acetonide in spring 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.690736

10.1517/14656566.2012.690736

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference

PubMed ID

22783878